Hologic to Present Groundbreaking Viera™ Portable Breast Ultrasound System at ECR 2018
--New product scheduled for global commercial availability in April 2018--

MARLBOROUGH, Mass., February 28, 2018 -- Hologic, Inc. (Nasdaq: HOLX) announced today that it will present the new Viera™ portable breast ultrasound system at the annual European Congress of Radiology (ECR) for the first time in Vienna, Austria. The system, expected to be available for purchase in Europe and the United States in April, is one of eight market-leading breast and skeletal health innovations being showcased on Booth x2/211.

The Viera system is a wireless, handheld ultrasound device that delivers accurate, high-resolution diagnostic images at the point of care, enabling optimization of clinical workflow and patient pathway. This innovative new system seamlessly transmits images to smart devices and picture archiving and communication systems (PACS) in the office, exam room or surgical suite, and allows facilities to add interventional breast ultrasound services for a fraction of the cost of comparable cart systems.

“As the global leader in breast cancer screening technology, Hologic continues to introduce breakthrough innovations that deliver superior clinical outcomes and experiences for clinicians and patients alike,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “The latest addition, our new Viera system, offers exceptional image quality and streamlined workflow, making it a natural and exciting addition to our growing portfolio of cutting-edge breast and skeletal health solutions.”

Booth visitors will also have the opportunity to experience the 3Dimensions mammography system, which is designed to be the fastest, highest resolution breast tomosynthesis system ever.[1] The 3Dimensions system launched in Europe in September 2017. It offers a variety of features designed to provide higher quality 3DÔ images for radiologists, enhanced workflow for technologists, and a more comfortable mammography experience, with low-dose options, for patients.

In addition, the 3Dimensions system will be available for hands-on experiences in a mobile unit, located by the main conference center. Additional products on display on Booth x2/211 will include the:

  • Affirm® prone breast biopsy system
  • New Brevera® breast biopsy system with CorLumina® imaging technology
  • New Fluoroscan® InSight® FD Mini C-arm extremities imaging system
  • Horizon® DXA system
  • i-View™ software
  • SmartCurve™ breast stabilization system

Throughout ECR, Hologic will host a range of interactive workshops, suitable for all levels of experience, on topics including 3D™ image-guided breast biopsy solutions, contrast-enhanced 2D mammography, and advancements in 3D™ Mammography. In addition, the Company will host a symposium, “Transforming breast biopsy with real-time imaging; impact on clinical routine,” led by Dr. Scaperrotta (Italy), Dr. Teh (United Kingdom) and Dr. Tejerina (Spain). The symposium will take place on Thursday, March 1 at 12:30 p.m.

A series of “Meet the Experts” sessions, where leading clinicians and representatives from the Company’s screening, interventional and skeletal teams will present on hot topics for breast radiologists and radiographers, will take place throughout the show. For more information, please visit or stop by Hologic’s Booth x2/211.

About Hologic, Inc.

Hologic, Inc. is an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment. For more information on Hologic, visit

Hologic, 3D, 3D Mammography, 3Dimensions, Brevera, CorLumina, Fluoroscan, InSight, Quantra, SmartCurve, and Viera are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

Forward-Looking Statements

This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to

Media Contact:

Jane Mazur

+1 508.263.8764 (direct)

+1 585.355.5978 (mobile)





[1] Data on file